Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9800	Companies
196463	Keywords
127467	Articles
104446	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 03/03/2025 at 14:00, 11 months ago

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, officially launched in the United States and European Union, offering comparable efficacy and safety. Formycon AG and Fresenius ensure successful market access

Formycon AG Launch Biosimilar Stelara Otulfi
BRIEF

published on 02/25/2025 at 06:35, 11 months 7 days ago

Le FYB203 de Formycon reçoit l'approbation réglementaire britannique

Réglementation Au Royaume-Uni Approbation Des Biosimilaires Formycon FYB203 Traitement Ophtalmique Partenariat Avec Teva
BRIEF

published on 02/25/2025 at 06:35, 11 months 7 days ago

Formycon's FYB203 Receives UK Regulatory Approval

UK Regulatory Biosimilar Approval Formycon FYB203 Ophthalmic Treatment Teva Partnership
PRESS RELEASE

published on 02/25/2025 at 06:30, 11 months 7 days ago

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA

Regulatory Approval UK Biosimilar Formycon AHZANTIVE
BRIEF

published on 02/24/2025 at 11:31, 11 months 7 days ago

Formycon AG: Price Target Adjusted Amid Market Pressures

Buy Recommendation Formycon AG Price Pressure Biosimilar Market Investment Reduction
BRIEF

published on 02/24/2025 at 11:31, 11 months 7 days ago

Formycon AG : Objectif de cours ajusté en raison des pressions du marché

Formycon AG Recommandation D'achat Pression Sur Les Prix Réduction Des Investissements Marché Des Biosimilaires
PRESS RELEASE

published on 02/24/2025 at 11:26, 11 months 7 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 11 months 12 days ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
BRIEF

published on 02/20/2025 at 06:35, 11 months 12 days ago

Formycon dévoile les données cliniques du biosimilaire d'ustekinumab FYB202 au congrès de l'ECCO

Formycon AG FYB202 Biosimilaire Approbation Réglementaire Données Cliniques
PRESS RELEASE

published on 02/20/2025 at 06:30, 11 months 12 days ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab

Accesswire

Published on 02/04/2026 at 02:15, 8 hours 47 minutes ago

Future Fuels Announces $2 Million LIFE Flow-Through Offering
Published on 02/04/2026 at 00:00, 11 hours 2 minutes ago

Sintana Energy Inc. Announces VMM-37 Resolution
Published on 02/03/2026 at 23:30, 11 hours 32 minutes ago

FutureGen Industries Retains Market-Making Services
Published on 02/03/2026 at 23:12, 11 hours 50 minutes ago

Appointment of Credit Advisor for Stage 1 Operations
Published on 02/03/2026 at 22:30, 12 hours 32 minutes ago

Green Bridge Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$4 Million

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 10:56, 5 minutes ago

Conference call on the results for the 1st quarter 2025/2026 (ending 31 December 2025) on 11 February 2026
Published on 02/04/2026 at 10:52, 10 minutes ago

EQS-Adhoc: Limes Schlosskliniken AG: Preliminary group result (unaudited) / forecast 2026
Published on 02/04/2026 at 10:15, 47 minutes ago

From Banks of Yellow River to Dining Tables Worldwide: Lanzhou Beef Noodles Get a Makeover through Cross-industry Fusion
Published on 02/04/2026 at 10:10, 52 minutes ago

Dahua Technology Showcases Intelligent LED Solutions at ISE 2026
Published on 02/04/2026 at 10:05, 57 minutes ago

Huawei to Launch Innovative New Products in Madrid, Showcasing a Dazzling Lineup

Les Echos

Published on 02/03/2026 at 19:18, 15 hours 43 minutes ago

Paulic Meunerie - Chiffre d'Affaires 2025
Published on 02/03/2026 at 18:00, 17 hours 2 minutes ago

Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
Published on 02/03/2026 at 17:45, 17 hours 17 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 02/03/2026 at 17:45, 17 hours 17 minutes ago

Revenue growth in 2025 to €11.2m (+5%)
Published on 02/03/2026 at 17:45, 17 hours 17 minutes ago

Chiffre d’affaires 2025 en croissance à 11,2 M€ (+5%)

View all LES ECHOS COMFI WIRE